ArticleCureus2026
Posterior Reversible Encephalopathy Syndrome (PRES) as the Initial Presentation of Systemic Lupus Erythematosus With Lupus Nephritis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity most often associated with acute hypertension, renal failure, or autoimmune diseases. PRES as an initial manifestation of systemic lupus erythematosus (SLE) has been described but remains rare. Early recognition and treatment of the underlying condition are essential to ensure a favorable outcome. We report the case of an 18-year-old North African female residing in Belgium, admitted for gastrointestinal symptoms associated with severe arterial hypertension, acute renal failure, and neurological manifestations, including seizures and visual disturbances. Brain magnetic resonance imaging (MRI) showed bilateral posterior and basal nuclei hyperintensities consistent with PRES. Laboratory investigations revealed impaired renal function and immunological abnormalities, including positive antinuclear and anti-double-stranded DNA antibodies. Further evaluation confirmed lupus nephritis, establishing the diagnosis of SLE. Treatment included prompt blood pressure control, antiepileptic therapy, high-dose corticosteroids, and immunosuppressive therapy targeting lupus nephritis. The patient experienced complete neurological recovery with resolution of seizures and visual symptoms. Follow-up imaging demonstrated radiological improvement, and renal function gradually recovered under immunosuppressive treatment. This case illustrates PRES as a rare inaugural manifestation of SLE in the context of hypertensive emergency and lupus nephritis. Early diagnosis and management of both neurological and systemic involvement are crucial to achieve complete neurological recovery and improve long-term outcomes. Strict blood pressure control and timely evaluation for SLE are critical in suspected PRES, and clinicians should be aware that atypical involvement of the basal ganglia may occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.